Commercial Sanofi posts upbeat sales as R&D pressure builds BioPharma DiveA string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over.CommercialRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) BioPharma Dive A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. CommercialRead full story Post navigation Previous: BBOT shakes up leadership as RAS competitors get more visibilityNext: Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026